Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ianalumab in previously treated primary immune thrombocytopenia
CTR20232611Phase 2Active
- Sponsor
- Novartis
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ianalumab in immune thrombocytopenia (ITP), sponsored by Novartis. Started Dec 2023; status: active.
02
Drugs
ianalumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20232611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232611.